IntraBio
Austin
About IntraBio
IntraBio is a biopharmaceutical company with a late-stage drug pipeline that includes novel treatments for genetic and neurodegenerative diseases. Their clinical programs leverage the expertise of their scientific founders from the University of Oxford and University of Munich, the preeminent experts and pioneers in discovering and developing small molecule drugs that modulate lysosomal function and intracellular calcium signaling. Their management team and business consultants have vast commercial and regulatory experience in drug product development, including all stages from small molecule manufacturing, clinical studies, and regulatory approvals in the USA and Europe. With their successful track record of drug development and commercialization, IntraBio’s team translates research in the fields of lysosomal biology, autophagy, and neurology into orphan drugs and treatments that will significantly improve the lives of patients, their caregivers, and families.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $50.6M
- Last round: Series Unknown (Mar 2024)
- Website: intrabio.com
- Phone: 8770 386-7402
Industries & Categories
Biotechnology, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/intrabio-44435 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.